Developing drugs for pediatricrare diseases. The company focuses on discovering the genetic basis for diseases and develops drugs that can intervene in the affected pathways.
Contact Information
Contact Information
Investors 2
| Date | Name | Website |
| 27.07.2022 | Ben Frankl... | sep.benfra... |
| - | Medical Ex... | medexcelca... |
Mentions in press and media 5
| Date | Title | Description |
| 16.06.2025 | Nobias Therapeutics Secures Preliminary FDA Alignment on Registrational Endpoints for NB-001 for Treatment of 22q11.2 Deletion Syndrome | Nobias Therapeutics Secures Preliminary FDA Alignment Nobias Therapeutics, a clinical-stage company developing novel small-molecule therapeutics for rare diseases, today announced that it has secured preliminary alignment with the U.S. Food... |
| 05.12.2024 | FDA Grants Rare Pediatric Disease and Orphan Drug Designations to Nobias Therapeutics for Treatment of 22q11.2 Deletion Syndrome | Nobias Therapeutics Nobias Therapeutics, a clinical-stage company developing novel small-molecule therapeutics for rare diseases, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted rare pediatric di... |
| 14.11.2024 | Nobias Therapeutics Announces Strategic Focus and New Leadership | Nobias Therapeutics Nobias Therapeutics, a clinical-stage company developing novel small-molecule therapeutics for rare diseases, has announced its intent to focus its resources on its development programs following receipt of positive data... |
| 16.04.2024 | Nobias Therapeutics Joins NVIDIA Inception Program for Startups | Nobias Therapeutics Nobias Therapeutics, a biotechnology company pioneering artificial intelligence (AI)-based deep phenotyping techniques to discover advanced therapeutics, today announced it has joined NVIDIA Inception, a program that nur... |
| 19.04.2022 | Ben Franklin Approved $3.1M in 14 Early Stage Companies |